Application of combined gene in esophageal squamous carcinoma

Abstract

The invention relates to the technical field of biological medicines, and discloses an application of a combined gene in preparation of a product for diagnosing esophageal squamous carcinoma. The combined gene comprises the following genes of a CCL20 gene, a GSTP1 gene, an HSPB1 gene, a KRT14 gene, a KRT15 gene, an S100A8 gene, an S100A9 gene and a TACSTD2 gene. The invention also discloses an application of the combined gene in preparation of a pharmaceutical composition for treating the esophageal squamous carcinoma. Compared with single gene expression detection of the esophageal squamous carcinoma in the prior art, the combined gene has higher specificity and higher diagnosis efficiency, can significantly improve the detection sensitivity and specificity, can accurately, conveniently and efficiently perform esophageal squamous carcinoma early diagnosis and large-scale screening, and fills up the blank of an existing diagnosis technology, so that effective treatment measures are provided for esophageal squamous carcinoma patients in time, and prognosis is improved.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of a combined gene in esophageal squamous cell carcinoma. Background technique [0002] Esophageal cancer (EC) is a malignant tumor of the digestive tract originating from human esophageal epithelial cells. The main pathological types are squamous cell carcinoma and adenocarcinoma. While the incidence of esophageal cancer is increasing year by year, its overall 5-year survival rate is only hovering at 15%-25%. China is a country with a high incidence of esophageal cancer. Esophageal cancer has become one of the four most common malignant tumors in my country. Patients with advanced disease often suffer from severe dysphagia, malnutrition, and even cachexia, which seriously affects the physical and mental health of the people. came a heavy burden of disease. [0003] The poor prognosis of esophageal cancer is closely related to the delay in diagnosis. Due to t...

AI Technical Summary

Problems solved by technology

[0003] The poor prognosis of esophageal cancer is closely related to the delay in diagnosis. Due to the insidious onset of esophageal cancer, atypical early symptoms, and the lack of effective large-scale screening methods, many patients have advanced to middle and late stages when they are diagnosed, and it is difficult to completely remove the tumor. And there are different degrees of lymph node involvement and distant metastasis, which brings great difficulties to the follow-up treatment

At present, the most commonly used diagnostic methods for esophageal cancer in clinic are upper gastrointestinal endoscopy and biopsy pathological examination, but this kind of invasive examination is costly, complicated to operate, and will bring different degrees of discomfort to the subjects, so it is not suitable for large-scale scale application

Existing imaging examinations such as CT scan and upper gastrointestinal barium contrast cannot meet the needs of early diagnosis and extensive screening

Traditional serum tumor markers are limited in the early diagnosis of esophageal cancer due to their low sensitivity and specificity

Images